4 Drug-Resistant Germs Threatening Public Health

Drug-resistant infections are no longer a distant medical concern. They affect hospitals, nursing homes, communities, sexual-health networks, and households. In the United States, drug-resistant germs kill more than 50,000 people each year, according to reporting on the Centers for Disease Control and Prevention’s antimicrobial-resistance findings Source 1.

The CDC’s broader threat assessment identifies 19 drug-resistant organisms as urgent or serious public-health threats Source 5.

This article examines four important examples: carbapenem-resistant Enterobacterales, Candida auris, carbapenem-resistant Acinetobacter baumannii, and drug-resistant Neisseria gonorrhoeae. They represent different forms of antimicrobial resistance, from hospital-acquired bacterial infections to resistant fungal disease and sexually transmitted infection.

Resistance does not always make an infection impossible to treat. It does, however, reduce the number of effective medicines. Treatment may become longer, more toxic, more expensive, and more dependent on specialized laboratory testing.

What Antimicrobial Resistance Means

Antimicrobial resistance occurs when a microorganism survives a medicine designed to kill it or stop its growth. Bacteria can resist antibiotics, fungi can resist antifungal drugs, viruses can resist antiviral medicines, and parasites can resist antiparasitic treatments.

People do not become resistant to antibiotics; the germs causing an infection change.

How germs become resistant

Resistance can develop through genetic mutations. Microorganisms can also acquire resistance genes from other microorganisms. When an antimicrobial medicine kills susceptible germs, resistant ones may survive and multiply. This process is called selection pressure.

Resistance genes can move between bacteria, allowing resistance to spread quickly. A single organism may eventually carry several resistance mechanisms, leaving clinicians with few effective treatments.

Unnecessary antibiotics, inappropriate drug selection, incorrect dosing, and prolonged exposure can accelerate resistance. Antibiotics also do not treat viral illnesses such as most colds and influenza.

Patients should take antimicrobial medicines only under appropriate medical guidance. They should not share prescriptions, save leftover medicine, or change treatment without contacting the prescribing clinician. The correct treatment duration depends on the infection, medicine, resistance pattern, and individual health.

Why treatment can fail

Resistant germs can defeat medicines by producing enzymes that destroy the drug, altering the drug’s cellular target, preventing the medicine from entering the cell, or pumping it back out.

Some microorganisms form biofilms: protective communities attached to surfaces such as medical devices or damaged tissue. Biofilms can make germs harder to eliminate and may contribute to persistent infections.

Because resistance is not always predictable, clinicians may need cultures and susceptibility testing. These tests identify the organism and determine which medicines remain effective.

1. Carbapenem-Resistant Enterobacterales

Enterobacterales are a large group of bacteria that includes Escherichia coli and Klebsiella species. Some live harmlessly in the intestinal tract, but they can cause serious disease when they enter the urinary tract, bloodstream, lungs, wounds, or other normally sterile areas.

Carbapenems are powerful antibiotics often reserved for severe infections caused by bacteria resistant to other drugs. Carbapenem-resistant Enterobacterales, commonly called CRE, can survive these important last-line medicines.

Some CRE bacteria produce carbapenemase enzymes that break down carbapenem antibiotics before they can work. Other resistance mechanisms can further reduce treatment options.

Infections caused by CRE

CRE can cause urinary tract infections, pneumonia, bloodstream infections, wound and surgical-site infections, and, rarely, meningitis.

A person may carry CRE without symptoms. This state is called colonization. Colonized individuals can still spread the bacteria, and patients with weakened defenses may develop invasive disease.

How CRE spreads

CRE spreads through contact with contaminated hands, surfaces, equipment, or medical devices. Hospitals and long-term care facilities face particular risks because patients may be vulnerable, receive frequent antibiotics, or require invasive care.

Catheters, ventilators, and intravenous lines can provide routes for bacteria to enter the body. Improperly cleaned equipment can also transmit organisms between patients.

Treatment depends on the infection site, resistance mechanism, and patient’s condition. Some cases require newer targeted medicines, combination therapy, or consultation with an infectious-disease specialist.

Prevention includes careful hand hygiene, thorough cleaning and disinfection, appropriate use and prompt removal of invasive devices, laboratory testing, screening or isolation protocols when indicated, and clear communication during patient transfers.

2. Candida auris

Candida auris is a drug-resistant fungus that can cause severe infections, particularly in health care settings. Unlike common superficial yeast infections, it can enter the bloodstream, infect wounds, and spread between patients.

The fungus can survive on surfaces and medical equipment for extended periods. It may resist one or more major classes of antifungal medicine. Some strains resist multiple classes, making treatment especially difficult.

Who faces the greatest risk?

Higher-risk groups include people who spend extended periods in hospitals, live in nursing homes or long-term care facilities, use central lines, feeding tubes, or ventilators, recently underwent surgery, have weakened immune systems, have multiple serious medical conditions, or have received repeated courses of antibiotics or antifungals.

Many people carry C. auris without symptoms. Colonization can last a long time and may allow the organism to spread.

Symptoms and infection control

C. auris can cause bloodstream infections, wound infections, and ear infections. Symptoms vary by infection site and may resemble those of other serious infections. Bloodstream disease can cause fever, chills, low blood pressure, confusion, or other signs of systemic illness.

Routine laboratory methods may misidentify C. auris as another yeast. Specialized testing is often needed when the organism is suspected.

Prevention includes contact precautions, specialized laboratory identification, environmental cleaning with products effective against C. auris, and careful disinfection of shared equipment. Clinicians select antifungal therapy based on laboratory results and the patient’s condition.

3. Carbapenem-Resistant Acinetobacter

Carbapenem-resistant Acinetobacter baumannii is strongly associated with health care environments. It can survive on surfaces and equipment, and carbapenem resistance removes one of the major antibiotic options used for serious infections.

This organism may cause ventilator-associated pneumonia, bloodstream infections, urinary tract infections, wound infections, and infections after surgery or severe trauma. Patients in intensive care are particularly vulnerable. Risk increases with ventilator use, open wounds, prolonged hospitalization, invasive devices, and weakened immunity.

Treatment is difficult because the organism may resist several antibiotic classes simultaneously. Some strains produce enzymes that inactivate antibiotics, while other mechanisms prevent drugs from reaching effective concentrations inside bacterial cells.

Depending on susceptibility results, treatment may require highly specialized or potentially toxic medicines. Clinicians must balance infection control with the risks of available drugs.

Hospitals reduce spread through strict hand hygiene, contact precautions, thorough environmental cleaning, dedicated or properly disinfected equipment, careful ventilator and catheter management, wound-care protocols, and surveillance for unusual resistance patterns.

4. Drug-Resistant Neisseria gonorrhoeae

Neisseria gonorrhoeae causes gonorrhea, a sexually transmitted infection. The bacterium has progressively developed resistance to several medicines used against it, leaving fewer dependable treatment options.

Resistance recommendations can change as surveillance identifies new patterns. Clinicians therefore need current guidance and, in some situations, follow-up testing to confirm that treatment worked.

Symptoms and complications

Gonorrhea may cause painful urination, genital discharge, pelvic pain, testicular pain or swelling, rectal discomfort or discharge, and sore throat. Many throat and rectal infections cause few or no symptoms.

Untreated infection can lead to pelvic inflammatory disease, infertility, ectopic pregnancy, chronic pelvic pain, or infection of the testicles. In rare cases, the bacteria enter the bloodstream and affect the joints, skin, or other organs. Gonorrhea can also increase the risk of acquiring or transmitting HIV.

People should not self-treat suspected gonorrhea with leftover antibiotics. The wrong drug may fail to cure the infection and may further complicate resistance.

Prevention includes consistent condom or barrier-method use, testing after potential exposure, recommended screening, and prompt partner evaluation. Patients should follow instructions about sexual abstinence until treatment is complete. Clinicians may recommend follow-up testing, particularly after treatment for throat infection or when treatment failure is suspected.

Why New Antibiotics Are Not Arriving Fast Enough

Scientific barriers are substantial. Gram-negative bacteria have protective outer membranes that can prevent medicines from entering. Resistance mechanisms may affect multiple drugs at once, and bacteria can develop resistance to new medicines after widespread use.

Antibiotic development is also economically difficult. Most antibiotics are taken for short periods, unlike medicines for chronic diseases. New drugs may need to be reserved for the most resistant infections, which limits sales. Research, clinical trials, regulatory review, manufacturing, and post-market surveillance are expensive.

These conditions can discourage private investment even when public-health need is high. Nature has highlighted the scientific, economic, and regulatory obstacles involved in developing antibiotics for resistant Gram-negative bacteria Source 9.

Solutions require public-health investment, research funding, incentives for drug development, reliable resistance surveillance, and stewardship programs that preserve new medicines. Diagnostics, vaccines, and non-antibiotic treatments also require support.

How Resistant Germs Spread Beyond Hospitals

Hospitals and long-term care facilities create conditions that favor transmission: vulnerable patients, invasive devices, shared equipment, frequent antimicrobial use, and close contact between staff and patients.

Resistant organisms can also spread in communities. Households, workplaces, travel, sexual networks, and nursing homes can all contribute. A person may carry a resistant organism without symptoms and introduce it into a health care setting.

Resistance is also connected to animal health, food production, and the environment. Antimicrobial use in people and animals can create selection pressure, while contaminated water and soil can help resistant organisms and resistance genes circulate. This interconnected view is known as One Health.

What Individuals Can Do

People can reduce risk by:

• Taking antimicrobials only when prescribed or recommended
• Following the prescribed dose and schedule
• Never sharing or saving medicines
• Asking whether an antibiotic is necessary
• Avoiding pressure for antibiotics for viral illnesses
• Washing hands regularly
• Keeping vaccinations current
• Cleaning and covering wounds
• Handling food safely
• Practicing safer sex and following testing guidance
• Staying home when advised during contagious illness

Patients should tell clinicians about recent hospital stays, international travel, previous resistant infections, and recent antimicrobial use. They should follow instructions about wound care, isolation, testing, and partner notification.

What Health Systems and Policymakers Must Do

Health systems need strong surveillance to identify resistant organisms, treatment failures, and outbreaks. Hospitals, laboratories, long-term care facilities, and public-health agencies must share timely information.

Infection prevention requires adequate staffing, training, hand-hygiene programs, environmental cleaning, laboratory capacity, and access to protective equipment. Long-term care facilities need the same attention as hospitals because residents may have prolonged exposure to shared staff, equipment, and medical devices.

Antimicrobial stewardship programs help clinicians choose the right medicine, dose, and duration. They also encourage prescription reviews when laboratory results become available and reduce unnecessary use of broad-spectrum drugs.

Policymakers can support research into antibiotics, antifungals, diagnostics, vaccines, and alternative treatments. New medicines must be preserved through responsible prescribing, or resistance may limit their usefulness soon after introduction.

Conclusion: Resistance Requires Prevention as Well as Treatment

These four organisms show why antimicrobial resistance is a broad public-health threat. CRE and carbapenem-resistant Acinetobacter can cause severe health care-associated infections. Candida auris combines environmental persistence with antifungal resistance. Drug-resistant gonorrhea can spread silently through communities and leave fewer reliable treatments.

Many resistant infections remain treatable. The danger is that treatment may require specialized testing, toxic medicines, longer hospital stays, or urgent expert care.

Preventing infections is as important as developing new medicines. Hand hygiene, vaccination, safer sex, appropriate device use, environmental cleaning, laboratory surveillance, and responsible antimicrobial prescribing can all slow the spread of resistance.

Frequently Asked Questions

What are antimicrobial-resistant germs?

They are bacteria, fungi, viruses, or parasites that no longer respond effectively to medicines designed to treat them. Resistance can make infections harder to cure and easier to spread.

Are drug-resistant infections always fatal?

No. Many can still be treated. Outcomes depend on the organism, infection site, resistance pattern, timing of treatment, and patient’s overall health.

Can resistant germs spread outside hospitals?

Yes. They can spread in households, communities, nursing homes, sexual networks, workplaces, and during travel. Hospitals remain high-risk settings because patients are often vulnerable and exposed to invasive devices.

How can people prevent antimicrobial resistance?

Use antimicrobials only as directed, follow treatment instructions, avoid sharing or saving medicine, wash hands, keep vaccinations current, practice safer sex, and follow infection-control guidance.

Why can’t scientists simply develop more antibiotics?

New antibiotics are scientifically difficult and expensive to develop. Gram-negative bacteria are particularly challenging, and limited commercial returns can reduce investment.

Should someone stop an antibiotic after feeling better?

No one should change or stop treatment without speaking with the prescribing clinician. The appropriate duration depends on the infection, medicine, and individual circumstances.